Opportunity in Biopharmaceuticals

Monoclonal antibodies are a well-established class of biotherapeutic in a rapidly expanding market. Biotechnology companies worldwide are adopting innovative approaches to discovering the antibody product blockbusters of the future. Discerna is applying its proprietary technologies and expertise in protein engineering and Ribosome Display to the discovery of novel products, for application in human healthcare and beyond.

Fundamental to the safe, targeted development of drugs is a mature understanding of disease biology and the role of specific proteins in its underlying causation. Functional protein microarrays hold tremendous potential for analysis of protein pathways and identification of novel protein interactions in disease. Discerna has developed a series of protein array technologies that address drug discovery needs in this area, as well as complementing the unique properties of Ribosome Display.